As potential sale details unfold, Life Technologies continues to make significant advances in stem cell research and molecular diagnostics. Earlier this month, Life Technologies signed a collaborative stem cell products research agreement with Harvard University. In another win last week, the company received an FDA clearance to market a molecular diagnostic assay made by the Quidel Corporation, for use with Life Technologies’ equipment and software. The test is helpful to at-risk elderly patients with respiratory infections.
Ronnie Andrews, president of Medical Sciences at Life Technologies said, "Molecular diagnostic assays have become the gold standard for infectious disease testing in the clinical lab… Molecular testing is the fastest-growing segment of the diagnostics market, and Life Technologies' deep expertise in real-time PCR instrumentation, together with our demonstrated effectiveness in pursuing regulatory pathways for our instruments, uniquely positions Life to become a leader in the diagnostics market."
GuruFocus research shows that Life Technologies Corp. began operations as a California partnership in 1987 and incorporated in California in 1989. The company has a market cap of $10.9 billion; its shares are traded around $63.59 with a P/E ratio of 26.13 and P/S ratio of 3.0211. Life Technologies Corp. had an annual average earnings growth of 25.1% over the past 10 years. Life Technologies Corp. employees 10,000 employees, and has over 1,500 scientists in 180 countries.
According to GuruFocus, the top three stakeholders of LIFE are PRIMECAP, with 14,793,545 shares; Guru John Paulson who added 3.6% to his position quarter ending Dec. 31, 2012, with current shares at 14 million, and Guru Larry Robbins who recently added 0.88% to his LIFE position, for a total of 11,545,648 shares, on Feb. 14, 2013.
Here are the holding histories of the three major Guru stakeholders:
PRIMECAP holding history:
Larry Robbins holding history:
John Paulson holding history:
Articles on GuruFocus.com
See GuruFocus background story on LIFE.